Hutchison Medicine: Do not blindly follow the trend, and strive to make the "China Plan" go global

It is true that in the past few years, biopharmaceuticals have been a more eye-catching target for some investors, and investment institutions will also pay attention to the company's pipeline layout in biopharmaceuticals and immuno-oncology, while chemical drugs have received relatively little attention
.

However, Dr.

It is true that in the past few years, biopharmaceuticals have been a more eye-catching target for some investors, and investment institutions will also pay attention to the company's pipeline layout in biopharmaceuticals and immuno-oncology, while chemical drugs have received relatively little attention

In this regard, Dr.
Su Weiguo, Chief Scientific Officer of Hutchison Medicine, who joined Hutchison Medicine 16 years ago and devoted himself to the brand-new innovative medicine industry, said that Hutchison Medicine’s development concept is based on “founding a foothold in the local area and developing affordable and affordable products for the Chinese as soon as possible.
“Well-used, high-quality new drugs” are based on the responsibility and mission
.

The company will always pursue long-term development goals, and will not abandon international standards in pursuit of faster listing in China-although this may benefit in the short term, it may abandon the global development pattern

Dr.
Weiguo Su, Chief Scientific Officer of Hutchison Medicine

"Three major tinni", from China to the world

Fruquintinib, Sofatinib and the upcoming Sevotinib-these three products independently developed by Hutchison Medicine were born from the laboratory in Zhangjiang, Shanghai.
They have been marketed or tested throughout the country as listed drugs or experimental drugs.
, Is embarking on a journey to sea-Hutchison Medicine, which was born in 2000, brings her fruitful research and development results to the world
.

Fruquintinib was first born, a national Class 1 new drug that was completed in China from discovery to the launch of the new drug.
In 2007, it was synthesized in the laboratory in Zhangjiang, Pudong, Shanghai
.

In September 2018, the drug was approved by the National Food and Drug Administration for the treatment of patients with metastatic colorectal cancer, and was included in the National Medical Insurance Drug List from January 1, 2020

In June 2018, the top international medical journal "Journal of the American Medical Association" (JAMA; impact factor: 47.
661) published online the full text of the research results of the FRESCO study, and the clinical research of new anti-tumor drugs in China achieved a zero breakthrough in "JAMA"
.

Data show that after Hutchison Pharmaceutical's Fruquintinib was approved for listing in September 2018, the terminal sales of China's public medical institutions exceeded 17.

At present, Fruquintinib is conducting Phase III clinical studies in about 165 research centers in 14 countries including the United States, Europe and Japan, and is fully committed to promoting Chinese innovation to the international stage
.

If fruquintinib means a "progress" for the treatment of colorectal cancer, then sofatinib means a "revolution" for the treatment of endocrine tumors-the emergence of sofatinib is for Neuroendocrine tumors with very limited treatments on a global scale provide new treatment options.
It also proves to the global medical community that Chinese innovative drugs are on the rise, and Chinese companies are providing "Chinese solutions" for the unmet medical needs of the world
.

Sofantinib is also a "native-born" innovative drug.
It was independently discovered and developed by Hutchison Medicine, completed phase III clinical trials, was approved for listing in China, and declared for listing in the United States-a process that lasted more than 14 years
.

In December 2020, Sofatinib was approved by the National Food and Drug Administration of China for the treatment of neuroendocrine tumors of non-pancreatic origin; the new drug application for pancreatic neuroendocrine tumors was also accepted by the National Food and Drug Administration in September 2020

At the same time, the internationalization of Sofatinib is also advancing rapidly
.

In 2020, Sofantinib will successively participate in the American Society of Clinical Oncology (ASCO) annual meeting, the European Society of Medical Oncology (ESMO) annual meeting and other international authoritative conferences, and successively obtain the "Orphan Drug" qualification of the US Food and Drug Administration (FDA) And two "fast track" qualifications

In August 2020, the market application of another potent and highly selective oral small molecule MET inhibitor independently developed by Hutchison Medicine, Saivotinib, was again included in the priority review.
This is also the priority of Saivotinib.
The first new drug marketing application submitted worldwide
.

At present, Hutchison Medicine has 10 innovative drugs in the clinical stage, and 4 other innovative drug candidates in the pre-clinical stage are currently under New Drug Clinical Trial Application (IND), and are expected to enter clinical trials in the next 12 to 18 months

Improve accessibility and get through the "last mile"

It is true that in the past few years, biopharmaceuticals have been a more eye-catching target for some investors.
Investment institutions will also pay more attention to the pipeline layout of enterprises in biopharmaceuticals and immuno-oncology, while chemical drugs have received relatively little attention.

.

However, Dr.
Weiguo Su, Chief Scientific Officer of Hutchison Medicine, said that in clinical practice, chemical drugs and biological drugs, macromolecules and small molecules have advantages and complement each other.
We need to focus more on unmet clinical needs.
Aspect, rather than blindly follow suit
.

Dr.
Su Weiguo said that the emergence of PD-1 has undoubtedly brought good news to countless tumor patients, but at the same time, the response rate of PD-1 is limited, and a large number of clinical patients still do not have a good solution
.
Therefore, instead of joining the PD-1 "Melee", we pay more attention to the part of patients who cannot be treated by PD-1
.

In order to meet this vision, Hutchison Medicine’s rich pipeline covers as many mechanisms of action and tumor indications as possible-whether it is a macromolecular monoclonal antibody targeting cell surface protein receptors, or a small molecule drug that enters the cell, as well as precision "Positioning Missile" ADC drugs, and Huang Medicine have their layouts
.
At present, several core products in the R&D pipeline are based on global quality.
Through systematic and solid research and development, they fully understand the scientific nature of the products and the differences in indications for patients at home and abroad, and they have achieved international authority in the field.
Fully recognized
.

As Dr.
Su Weiguo said: "As an enterprise, we must have lofty goals.
The development philosophy of Hutchison Medicine is based on the responsibility and mission of'founding a foothold in the local area and developing new drugs that are affordable, well-used, and high-quality for Chinese people.
' On the basis of this, there is also an extremely important point, which is to always firmly pursue long-term development goals, instead of abandoning international standards just for the pursuit of faster listing in China.
Although this may benefit in the short term, it may give up face-to-face The grand pattern of global development"
.

It can be said that the core products in the Hutchison R&D pipeline are based on global quality and have the potential for global registration
.
By fully understanding the scientific nature of the product and the differences in indications for domestic and foreign patient populations, we have embarked on the "fast lane" leading to the world
.

In addition to solving the problem of "no medicines available", solving the problem of drug availability is also a real clinical need in China
.
In order to maximize the availability of drugs, Hutchison Medicine has established its own oncology specialist commercialization team, which is responsible for quickly bringing innovative oncology drugs approved for marketing to patients and the market
.
At present, the commercialization team of this specialty has more than 400 people, covering more than 2,000 cancer hospitals in 30 provinces across the country
.
"

In response to this, Cui Yantong, senior vice president of Hutchison Pharmaceuticals, pointed out that in the past, almost all anti-cancer drugs in China were imported.
However, due to the global pricing mechanism of multinational pharmaceutical companies, many people have never used the latest drugs
.
And now we have the capability of independent innovation, can follow up quickly, and even make a "global new", and provide it to the common people at a price that benefits the people, and promote it internationally, so that patients all over the world can benefit from it
.

However, Cui Yantong also mentioned that some data pointed out that as of the third quarter of 2020, about 25% of the oncology innovative drugs included in the National Medical Insurance List in 2018-2019 were admitted to the hospital in 1,420 sample hospitals
.
In this regard, the industry pointed out that the reasons behind the difficulty in hospital admission of innovative drugs are complex.
Different hospitals have different functional positioning in the medical system, and the types of equipment are quite different
.
To get through the "last mile" of hospital admission for innovative drugs, the collaborative operation of manufacturing companies, medical institutions, and medical insurance departments is required
.

Witness the historical moment of industry development

The success story of innovative drugs is a long one.
From small molecular formulas to listed drugs that benefit patients, the wisdom of drug developers, the persistence of researchers and companies, and the investment and R&D environment are indispensable
.

Twenty years ago, as one of the earliest biopharmaceutical companies dedicated to the research and development of innovative drugs in China, Hutchison Pharmaceuticals took root in the Zhangjiang Free Trade Zone, established a world-class R&D engine, and formed a collection of drug discovery, development, registration, and production.
Integrated and commercialized operation capabilities
.
During this journey, China’s local biomedicine industry has started from scratch, innovative R&D companies have gradually increased, new drug review and approval policies have been continuously improved, and the review and approval speed of innovative drugs has been greatly shortened.
.
.
Hutchison Medicine has also become a local biomedical development in China.
Witnesses, participants and beneficiaries
of

Cui Yimin mentioned that in 2016, Hutchison Medicine became one of the first companies in Shanghai to participate in the pilot work of the MAH system.
Fruquintinib capsules, as the first batch of Shanghai drug marketing license holders, successfully applied for, was approved for listing, and successfully opened up.
In the sales and circulation link, the business license was registered for change on September 29, 2018, and the country's first business license to increase the business scope of "consignment production of drugs" was obtained
.
Fruquintinib is also the first Class 1 new drug approved for marketing under the Shanghai MAH pilot system, and has become a successful example of the practicality of China's MAH system
.

The new drug marketing applications of Sofatinib and Sevotinib have been included in the priority review, which greatly improves the review and registration efficiency of innovative drugs
.
The speed of the adjustment of the medical insurance catalogue has accelerated, and the speed at which innovative drugs are included in medical insurance has also increased, helping innovative drugs to benefit more patients
.
In the 2019 medical insurance catalog adjustment, the Medical Insurance Bureau has added and renewed more than 20 Class B anti-tumor drugs
.
Fruquintinib was included in the medical insurance just one year after it was listed.
This speed is unprecedented
.

It can be said that under the guidance of the country’s vigorous efforts to promote the development of biomedicine innovation and development, China’s innovative drug R&D field has gone through many years of hard work and accumulation.
From the initial follow-up of medical innovation, it has become a leader in some subdivisions.
And strive to be the leader in the future
.

As one of China’s first innovative pharmaceutical R&D companies focusing on the global market, through more than 20 years of continuous accumulation, Hutchison Medicine is expected to see new innovative drugs on the market in the next few years, and even out of the market.
International, to provide more effective and safer innovative "Chinese solutions" for patients in need around the world
.

At the same time, as Hutchison Pharma’s major innovative new drugs continue to enter the process of new drug listings, Hutchison Pharma’s GMP factory in Suzhou is further based in Shanghai and entering a new stage of industrialization and commercialization
.
In December 2020, the construction of the large-scale innovative drug production base of Hutchison Pharmaceuticals, located in Pudong, Shanghai, covering an area of ​​43 acres, will start construction.
, Soaring wings
.